Catherine Pearce - Jan 26, 2023 Form 4 Insider Report for CinCor Pharma, Inc. (CINC)

Role: Chief Operating Officer
Signature: /s/ Cathy Rude, Attorney-in-Fact
Stock symbol: CINC
Transactions as of: Jan 26, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/30/2023, 07:07 PM
Previous filing: Jan 19, 2023
Next filing: Feb 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CINC	Common Stock	Award		+15K	+10.7%		155K	Jan 26, 2023	Direct	F1
holding	CINC	Common Stock						1.5K	Jan 26, 2023	By spouse	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date.
F2	The securities are held by the Reporting Person's spouse. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her proportionate pecuniary interest therein.

Content

Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date.

The securities are held by the Reporting Person's spouse. The Reporting Person shares voting and investment control of the shares and may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her proportionate pecuniary interest therein.